scholarly journals Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons

2017 ◽  
Vol 20 (3) ◽  
pp. 508-519 ◽  
Author(s):  
Niels B. Dalsgaard ◽  
Tina Vilsbøll ◽  
Filip K. Knop
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Narrative Review ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

2018 ◽  
Vol 2018 ◽  
pp. 1-12 ◽  
Author(s):  
María Isabel del Olmo-Garcia ◽  
Juan Francisco Merino-Torres
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Cardiovascular Complications ◽  
Primary Objective ◽  
Receptor Agonists ◽  
Therapeutic Algorithms ◽  
Glucagon Like Peptide 1 ◽  
Cardiovascular Benefit

Diabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of treatments should be a primary objective when selecting treatment. Among all the drugs available, the compounds known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appear to be not just innocuous in terms of CVD but indeed to be beneficial. GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or arterial hypertension but also might show benefits on endothelial function, coronary ischaemia, and heart failure. On the other hand, recent clinical trials aimed at studying cardiovascular episodes have been conducted with GLP-1 RAs. Only liraglutide and semaglutide have shown superiority in cardiovascular benefit compared with placebo. Although many of the mechanisms by which liraglutide and semaglutide produce a cardiovascular benefit are still unknown it would be desirable for these benefits to be incorporated into the therapeutic algorithms routinely used in clinical practice. The purpose of this review is to explore GLP-1 RA actions not only in cardiovascular risk factors (glucose, weight, and hypertension) but also the possible effects on established cardiovascular disease.

Pro-oxidant–antioxidant balance (PAB) as a prognostic index in assessing the cardiovascular risk factors: A narrative review

2020 ◽  
Vol 19 ◽  
pp. 100272
Author(s):  
Hamideh Ghazizadeh ◽  
Maryam Saberi-Karimian ◽  
Maliheh Aghasizadeh ◽  
Reza Sahebi ◽  
Hamed Ghazavi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Prognostic Index ◽  
Narrative Review

scholarly journals The effects and associations of whole-apple intake on diverse cardiovascular risk factors. A narrative review

2020 ◽  
Vol 60 (22) ◽  
pp. 3862-3875
Author(s):  
Berner Andrée Sandoval-Ramírez ◽  
Úrsula Catalán ◽  
Lorena Calderón-Pérez ◽  
Judit Companys ◽  
Laura Pla-Pagà ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Narrative Review
Sign in / Sign up

Export Citation Format

Share Document